• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Ousted Valeant CEO Subpoenaed by Congress, Adding to Ackman Woes

Michael Pearson, the troubled drugmaker's outgoing CEO, is set to face Congress.
By JAMES PASSERI Mar 28, 2016 | 04:00 PM EDT
Stocks quotes in this article: VRX

The Senate Special Committee on Aging has been no friend to Valeant Pharmaceuticals (VRX). And the beleaguered drugmaker needs a friend now more than ever.

With VRX shares down more than 71% this year as of midday trading, it was announced Monday that Valeant's departing CEO Michael Pearson will face the panel on April 27 over allegations that Valeant unfairly hikes the prices of its drugs -- in some cases (most prominently highlighted by Democratic presidential candidate Hillary Clinton) at exponential levels from where patients had grown accustomed.

Pearson was ousted earlier this month as part of a broader management reshuffle, which included the addition of billionaire activist Bill Ackman and the vice chairman of his hedge fund, Pershing Square, to Valeant's board of directors. (Valeant has been the bane of Pershing Square's terrible 2015 performance, as Real Money reported.)

The Special Committee on Aging has been crusading against companies that have hiked prices on necessary drugs to exorbitant levels long before the arrest of Martin Shkreli in December, following an alleged drug-pricing scheme into companies Shkreli founded, Retrophin and MSMB Capital Management.

"Today's development with Martin Shkreli will not affect the Senate Aging Committee's bipartisan investigation into the sudden, aggressive price spikes of some decades-old drugs, which is not limited to one person or one company," the committee said at the time of Shkreli's arrest. "As we have said from the beginning, these price spikes have raised questions that are critically important to the American public¿and we will continue our investigation until we've found answers to those questions."

The congressional subpoena Monday does not bode well for Valeant shareholders, who are hoping the drugmaker can resolve such claims as well as investigations into the bookkeeping of its sales, in order to timely file a proper 10-K annual statement with the SEC. Any further delays could even prompt breaches on Valeant's debt covenants, which would likely encourage even more shareholders to flee.

And Ackman's plans to stage a turnaround at Valeant may also be frustrated by a recent warning issued by Sprout Pharmaceuticals, the company it acquired last year for about $1 billion, as Real Money reported. Sprout said in a March letter that Valeant was not honoring its acquisition agreement with Sprout, and must recognize terms of the deal including fair pricing of Sprout's drugs as well as limitations on how much of Sprout's operations are allowed to be cut.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Technology

More from Healthcare

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login